





AMENDMENTS TO THE CLAIMS





This listing of claims will replace all prior versions, and listings, of claims in the application:






Listing of Claims:



1. (withdrawn- currently amended) A method of treating ~~or preventing~~ a β -amyloid-related disease in a subject comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of
N-(6-aminoheptyl)-4-bromobenzamidine (compound #145),
4-bromo-*N*-{7-[(4-bromobenzimidoyl)-amino]-heptyl}-benzamide (compound #146),
N-hydroxy-4-(9-hydroxyaminononyloxy)-benzamidine (compound #147),
N-[7-(4-carbamimidoylbenzoylamino)-heptyl]-terephthalamic acid ethyl ester (compound #148),
N-[9-(4-carbamimidoyl-benzoylamino)-nonyl]-terephthalamic acid ethyl ester (compound #149),
4,4'-(pentamethylenediamidino)di(*p*-bromobenzene) (compound #150),
4,4'-(nonamethylenediamidino)di(*p*-bromobenzene) (compound #151),
4,4'-(nonamethylenediamidino)di(*p*-methoxybenzene) (compound #152),
4-methoxy-*N*-{2-[2-(4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-ethyl}-benzamidine (compound #153),
4,4'-(pentamethylenediamidino)di(*p*-methoxybenzene) (compound #154),
2,2'-(*p*-amidinophenylcarboxamido)-*N,N*-diethyl-*p*-amidinobenzamide (compound #155),
{4-[5-(*p*-aminophenoxy)-pentyloxy]-phenyl}-(4,5-dihydro-1*H*-imidazol-2-yl)-amine (compound #156),
4,4'-(nonamethylenedisulfamyl)di(amidinobenzene) (compound #158),
3,3'-(pentamethylenediaminocarbonyl)di(amidinobenzene) (compound #159),
4,4'-(tetramethylenediaminocarbonyl)di(amidinobenzene) (compound #160), and
pharmaceutically acceptable salts thereof.
2. (withdrawn- currently amended) The method according to claim 1, wherein said subject is in need of treating ~~or preventing~~ of said β -amyloid-related disease.
3. (canceled)
4. (canceled)

5. (withdrawn - currently amended) The method according to claim 2, wherein said β -amyloid-related disease is, Alzheimer's disease, Down's syndrome, ~~type II diabetes~~, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.
6. (withdrawn) The method according to claim 2, wherein said compound is adapted to be administered orally.
7. (withdrawn) The method according to claim 2, where said subject is a human.
8. (previously presented) A chemical compound selected from the group consisting of:









and pharmaceutically acceptable salts thereof.

9-22. (canceled)






23. (previously presented) A pharmaceutical composition comprising a compound according to claim 8, and a pharmaceutically acceptable vehicle.






24. (canceled)





25. (currently amended) A pharmaceutical composition for the treatment or prevention of ~~an~~ a β -amyloid-related disease comprising a therapeutically effective amount of a compound according to claim 8.

26. (currently amended) The composition according to claim 25, wherein said β -amyloid-related disease is Alzheimer's disease, Down's syndrome, ~~type II diabetes~~, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.

27. (new) A method for the treatment of Alzheimer's disease in a subject comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of








Application No.: 10/763,953
Group Art Unit: 1626

Docket No.: NBI-193
Examiner: J.M. Nolan



and pharmaceutically acceptable salts thereof.